Pharmaceutical Business Review
Anonymous User | Login

GSK Provides Update On Government Orders For H1N1 vaccine

Published: 04-Aug-2009

Vaccine will be available to governments from September onwards

GlaxoSmithKline (GSK) confirmed on 22nd July that it had contracts to supply 195 million doses of its pandemic (H1N1) 2009 adjuvanted influenza vaccine. It also had a variety of agreements in place with the US Government to supply pandemic products worth $250 million.

GSK also said that, since then, it has signed nine more government contracts for a further 96 million doses of the vaccine. This now brings the total number of doses ordered for GSK’s adjuvanted vaccine to 291 million.

The first supplies of the vaccine will be available to governments from September onwards, with shipments expected in the second half of 2009 and early 2010. The exact pace of delivery will be dependent on capacity and the yield of the influenza strain, said the company.

Mail sent successfully

Tell your friend about this article


Please enter a valid email address

Please enter your name

Please enter the mail body


Your Name: *
Your Email: *
Friend's Email: *
Email Body: *
 

Suppliers To This Sector

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

AR2i

Liquid Handling, Laboratory Material and Technology, Aparatus, Automation and Glassware ...

Lonza Custom Manufacturing

Bioresearch Products, Development Services and Manufacturing for Functional and Active Ingredients ...

NovAliX

Small Molecule Drug Discovery ...

Umetrics

Multivariate Data Analysis Software ...

ELPRO

High Quality Temperature and Humidity Dataloggers ...

Kuecept

Concept Formulation Design ...

White Papers

Browse A-Z

# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Your IP at Risk in Collaborations!

Free white paper: Ten steps to protect your R&D investment within partnerships. ...

Why, When and How to Conduct 14C Human Studies

Several risk-based strategies to assess metabolites exist. Whatever the strategy chosen, t ...

Why CAPA Still Matters

This free white paper explores the needs and effectiveness of correct CAPA control, how to ...

Water Treatment

From the control room to the downstream processing area and with an eye on utilities servi ...

Using the Mean Kinetic Temperature (MKT) As a Parameter to Determine Whether Perishable Goods Have Been Transported and Stored Correctly

Tecnosoft systems use MKT calculation to control the acquired values and report the user w ...

USB HotStart-IT for Real Time PCR

USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...

Related Companies

AstraZeneca PLC

AstraZeneca PLC (AstraZeneca) is a leading pharmaceuticals company engaged in the desig ...

Schering-Plough Corporation

Schering-Plough Corporation (Schering-Plough) is a pharmaceutical company focused on di ...

Amgen Inc.

Amgen Inc. (Amgen) is a biotechnology company that is focused on the discovery, develo ...

Abbott Laboratories

Abbott Laboratories (Abbott) is a global health care company. It is principally engaged ...

GlaxoSmithKline plc

GlaxoSmithKline plc (GSK) is a is a United Kingdom-based pharmaceutical, biological, a ...

Suppliers Product News

Novalyst Discovery and AliX Agree to Merge NovAliX Launch

Integrating structural biology and medicinal chemistry.

AliX and SOSHO to Sign Agreement for Protein Structure Determination of Intractable Targets

Breakthrough crystallisation technology for protein structure determination.

Kuecept and The School of Pharmacy Agree Key Drug Delivery Licensing

Kuecept Ltd and The School of Pharmacy, University of London agree key drug delivery licensing deals to facilitate the development of low solubility, poorly bioavailable compounds.

Synectix Pharmaceutical Solutions Now Called Kuecept

Synectix Pharmaceutical Solutions Ltd, the speciality drug development company, announced today that effective immediately, the company has changed its name to Kuecept Ltd.

Free Newsletter Sign-up

Sign up, and we will send you a free Pharmaceutical report on “ Combination Products – Evolution of the Medical Equipment Industry” from GlobalData worth $750

Please enter a valid email address